about
Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma.Simultaneous quantification of budesonide and its two metabolites, 6beta-hydroxybudesonide and 16alpha-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry.Pulmonary targeting of sustained release formulation of budesonide in neonatal rats.A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma.Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.Pharmacokinetics of the dietary supplement creatine.Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.New developments in corticosteroids.How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids.Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems.Metabolism of dynorphin A 1-13 in human blood and plasma.Advances in single-entity inhaled corticosteroid therapy.Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: perspectives on clinical relevance.Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy.Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stressSystemic exposure to fluticasone MDI delivered through antistatic chambers.Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids.Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids.Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.A sensitivity analysis of the modified chi-square ratio statistic for equivalence testing of aerodynamic particle size distribution.A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone.A stability analysis of a modified version of the chi-square ratio statistic: implications for equivalence testing of aerodynamic particle size distribution.A pharmacokinetic simulation tool for inhaled corticosteroids.Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.Pharmacokinetics of Orally Inhaled Drug Products.A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial allergic rhinitis: how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspension-based formulation?Single- and multiple-dose pharmacokinetics of oral creatine.In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers.Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report.[Biocytin13]dynorphin A 1-13 amide: a potential probe for the kappa-opioid receptor.Delta opioid receptors in human neuroblastoma cell lines.Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers.Population pharmacokinetics and pharmacodynamics of ciclesonide.Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications, determination of plasma protein binding and verification of percent labeled claim of various creatine products.
P50
Q30844824-A6E3D185-5993-4283-AD5C-FBD2240AE8EEQ31131540-EB6B96D5-0E39-4673-B2A3-DFFC72AC07C1Q31140719-44490F44-A944-45E8-B22C-C98F06A63E33Q33266210-114DCDA8-8CC0-4881-82E2-3C5B62F3DC1DQ33433116-F0297E51-7CCC-4051-8D64-3C3016F51833Q33493240-15C93E56-3E23-4910-BA0D-8B8D007B2723Q35148293-A8EA870D-7D8C-4691-A757-46CD8EA4E445Q35827816-BABB3D96-F638-43A5-BF3C-9C144B8998A5Q35848336-D4F585FA-A998-400C-A7EE-37F98EAE9C0BQ36212850-66526FC0-CEED-446B-BDB5-C3DD66D07F18Q36236904-A41C0490-10CC-45F7-8F7D-3B9978D31913Q36236962-3CF09F17-9FBF-431D-9B48-A80172A00215Q36316793-B3D3A2B7-C4BA-4916-82B3-DD262B82169AQ36672007-B7686A5A-2111-4E5C-B6BB-F81AF81F57B3Q36811286-5A7E591B-AFD3-49FD-8B7F-90A83BEE4A0EQ37035873-555BA323-2D2E-408D-83C5-A90A1855AC0BQ37110976-258771BA-0FCC-40F2-956D-583BCA5C3931Q37210877-670F798B-69D8-4C3E-BF0C-B052191C5D12Q37262679-F8744A3E-134B-4216-9B41-E518711BB08DQ38084738-97ABAEEA-6706-4672-9BA3-C253D72BBABFQ38992873-AE0446C8-7572-4887-B7C9-DF73DF3F618AQ40346985-87934F6E-78BD-46D9-B950-79B153B44967Q41854778-C3D005DE-4BCF-404D-BFB6-1EB80267C319Q41907641-2DAB9248-009D-49D8-B471-5EB371F3C0C2Q41997758-BC4DB077-3C2B-4CCB-A00E-7D2AB034E530Q42035782-B1F499DC-9CFE-4F3F-9289-0DA84E28A533Q42463930-6FFC4903-4D53-4212-B11A-014B2DF506BFQ42506344-65723B16-2A02-4E86-A889-9F768F322795Q42507245-882FD685-D003-4C70-A865-111EF41B690CQ42590354-F95E1421-53C6-4608-AA2C-F55A9529D756Q42593027-0E85ABE9-6B64-4FD3-8470-65818965BF03Q42677593-BAF19A97-06FC-4597-B711-A3FE6EA2C1DCQ42692472-9ACE1355-F0BB-483D-A3AB-A2D077ECAC22Q43898822-E26FE0A1-A8A8-46BD-BDDE-EFD4241B2631Q43923321-E6B86849-1C7D-4A9E-A856-BDEED4F8950AQ44345429-D8A3FA2B-792D-497A-B222-AF270192F633Q44347127-47B908D2-6114-420C-93B3-E8A6989BBFD7Q44349579-73F89A2E-4B10-40CC-8C9A-166F3A27D61BQ44424374-E4E3B2BA-2E75-4647-9B71-CF3220BFE143Q44530686-58FD3CC5-F010-4812-9E96-3F2374FE947D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guenther Hochhaus
@ast
Guenther Hochhaus
@en
Guenther Hochhaus
@es
Guenther Hochhaus
@nl
Guenther Hochhaus
@sl
type
label
Guenther Hochhaus
@ast
Guenther Hochhaus
@en
Guenther Hochhaus
@es
Guenther Hochhaus
@nl
Guenther Hochhaus
@sl
prefLabel
Guenther Hochhaus
@ast
Guenther Hochhaus
@en
Guenther Hochhaus
@es
Guenther Hochhaus
@nl
Guenther Hochhaus
@sl
P1006
P214
P244
P1006
P106
P1153
35584571100
P214
P244
P31
P496
0000-0002-7406-5558
P7859
lccn-n94802133